CN107949380B - 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂 - Google Patents

用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂 Download PDF

Info

Publication number
CN107949380B
CN107949380B CN201680020467.XA CN201680020467A CN107949380B CN 107949380 B CN107949380 B CN 107949380B CN 201680020467 A CN201680020467 A CN 201680020467A CN 107949380 B CN107949380 B CN 107949380B
Authority
CN
China
Prior art keywords
alkyl
substituted
group
phenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680020467.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107949380A (zh
Inventor
S·帕特奈克
M·泰勒
R·R·卡尔沃
J·J·马瑞干
N·索撒尔
郑伟
M·费勒-阿莱格雷
S·德哈什
P·专克
F·陈
Y·约安努
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Represented By Secretary Of United States Department Of Health And Human Services
Icahn School of Medicine at Mount Sinai
Original Assignee
United States Represented By Secretary Of United States Department Of Health And Human Services
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Represented By Secretary Of United States Department Of Health And Human Services, Icahn School of Medicine at Mount Sinai filed Critical United States Represented By Secretary Of United States Department Of Health And Human Services
Publication of CN107949380A publication Critical patent/CN107949380A/zh
Application granted granted Critical
Publication of CN107949380B publication Critical patent/CN107949380B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680020467.XA 2015-02-11 2016-02-11 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂 Active CN107949380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114840P 2015-02-11 2015-02-11
US62/114,840 2015-02-11
PCT/US2016/017504 WO2016130774A1 (en) 2015-02-11 2016-02-11 Benzenesulfonamide upregulators of npc1 for neimann-pick disease and other lysosomal storage disorders

Publications (2)

Publication Number Publication Date
CN107949380A CN107949380A (zh) 2018-04-20
CN107949380B true CN107949380B (zh) 2021-07-06

Family

ID=56614815

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680020467.XA Active CN107949380B (zh) 2015-02-11 2016-02-11 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂

Country Status (8)

Country Link
US (1) US10239830B2 (https=)
EP (1) EP3256116B1 (https=)
JP (1) JP6887389B2 (https=)
CN (1) CN107949380B (https=)
AU (1) AU2016219231B2 (https=)
CA (1) CA2976449C (https=)
IL (2) IL253896B (https=)
WO (1) WO2016130774A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111289749B (zh) * 2018-12-10 2023-04-14 北京蛋白质组研究中心 C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用
WO2021150695A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents
WO2022159566A1 (en) 2021-01-21 2022-07-28 Icahn School Of Medicine At Mount Sinai Benzenesulfonamide agonists of trap1 for treating organ fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325385A (zh) * 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 胃泌素和缩胆囊素受体配体
WO2013192165A2 (en) * 2012-06-20 2013-12-27 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
WO2015004212A1 (en) * 2013-07-09 2015-01-15 Tragex Pharma Inhibitor of neuropilin and use thereof for the treatment of neuropilin-related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
WO2004035545A2 (en) * 2002-10-18 2004-04-29 E.I. Du Pont De Nemours And Company Azolecarboxamide herbicides
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2648202A1 (en) 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
WO2014022841A1 (en) * 2012-08-03 2014-02-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325385A (zh) * 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 胃泌素和缩胆囊素受体配体
WO2013192165A2 (en) * 2012-06-20 2013-12-27 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
WO2015004212A1 (en) * 2013-07-09 2015-01-15 Tragex Pharma Inhibitor of neuropilin and use thereof for the treatment of neuropilin-related diseases

Also Published As

Publication number Publication date
WO2016130774A1 (en) 2016-08-18
EP3256116A4 (en) 2018-07-11
EP3256116B1 (en) 2022-08-17
AU2016219231A1 (en) 2017-09-28
JP2018510904A (ja) 2018-04-19
US20180044286A1 (en) 2018-02-15
IL253896A0 (en) 2017-10-31
IL253896B (en) 2019-09-26
CN107949380A (zh) 2018-04-20
IL268811A (en) 2019-10-31
AU2016219231B2 (en) 2020-08-20
CA2976449A1 (en) 2016-08-18
US10239830B2 (en) 2019-03-26
CA2976449C (en) 2022-08-09
AU2016219231A2 (en) 2017-09-28
EP3256116A1 (en) 2017-12-20
JP6887389B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
JP6061922B2 (ja) プロテイノパチーの処置方法
US9610358B2 (en) Targeted pharmacological chaperones
EP1896083B1 (en) A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
US20220409595A1 (en) Glucosylceramide synthase inhibitors
ES2564093T3 (es) Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
JP2009521468A (ja) Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
TW201117811A (en) Novel compositions for preventing and/or treating lysosomal storage disorders
JP2019513741A (ja) アイバカフトール類似体を含有するケイ素原子
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
EP2252288A1 (en) Treatment of protein folding disorders
CN107949380B (zh) 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂
JP2017511372A (ja) 脳アミロイドーシスを処置及び／又は予防する投与計画
US10543282B2 (en) Targeted peptide conjugates
Motabar et al. Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease-Chemotype 2
HK40004632A (en) A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
HK1216230B (en) A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant